FACT - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 2.8
✅ Positive
FACT exhibits a recent turnaround in profitability with a substantial Qtr profit recovery, indicating potential operational improvements or shifting market dynamics. The relatively low RSI of 43.2 suggests the stock may be undervalued compared to its historical performance and peers.
⚠️ Limitation
Fact’s negative ROE (-2.91%) and ROCE (4.93%) indicate challenges in generating returns from invested capital and operating profits, respectively, reflecting underlying operational inefficiencies or market headwinds. The significant Qtr Profit Variance (-94.5%) raises concerns about the sustainability of this recent profit recovery and warrants further investigation into the drivers behind it.
📉 Company Negative News
Recent news indicates a decrease in FII holdings and a negative EPS figure for the quarter, highlighting potential investor sentiment weakness despite the profit recovery. The appointment of a new marketing director is a strategic move but doesn’t immediately address underlying profitability concerns.
📈 Company Positive News
FACT has secured a contract with BPCL to supply 1.5 lakh tonnes of sulphuric acid, representing a revenue opportunity and bolstering future sales prospects. The appointment of Niranjan Sonak as Director (Marketing) signals management's focus on improving market reach and customer engagement strategies.
🏭 Industry
The chemical sector is currently experiencing fluctuating demand due to global economic uncertainty and supply chain disruptions, presenting both risks and opportunities for companies specializing in basic chemicals like sulphuric acid. Industry PE ratios generally sit around 16-20, suggesting a reasonable valuation benchmark for companies with similar operating characteristics.
🧾 Conclusion
We recommend an entry zone between 750 ₹ - 800 ₹ based on the current undervaluation reflected in its low RSI and historical profitability metrics. A long-term holding guidance would be to maintain exposure while closely monitoring the sustainability of the recent profit recovery, particularly regarding supply contracts and overall market demand for sulphuric acid. Fact’s future success hinges on efficiently executing this BPCL agreement and addressing underlying ROE/ROCE challenges.